Title:
TECHNOLOGY FOR EFFICIENT ACTIVATION OF NKT CELLS
Document Type and Number:
WIPO Patent Application WO/2017/188033
Kind Code:
A1
Abstract:
The present invention relates to a method for activating NKT cells and thus proliferating the NKT cells, producing IFN-γ and/or producing NKT cell ligand-pulsed human CD14-positive cells capable of strongly inducing cytotoxic activity. More specifically, this method is characterized by comprising culturing isolated CD14-positive cells in a medium that contains an NKT cell ligand and GM-CSF but substantially does not contain IL-4. Further, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14-positive cell line. More specifically, the method is characterized by comprising culturing isolated CD14-positive cells in a medium that contains an NKT cell ligand but substantially does not contain GM-CSF and IL-4. Furthermore, the present invention relates to a cell preparation comprising NKT cell ligand-pulsed human CD14-positive cells or an NKT cell ligand-pulsed human CD14-positive cell line and a pharmaceutical use of said cell preparation.
Inventors:
TANIGUCHI MASARU (JP)
SHIGEURA TOMOKUNI (JP)
AIHARA MINAKO (JP)
HANADA KEIGO (JP)
SHIGEURA TOMOKUNI (JP)
AIHARA MINAKO (JP)
HANADA KEIGO (JP)
Application Number:
PCT/JP2017/015383
Publication Date:
November 02, 2017
Filing Date:
April 14, 2017
Export Citation:
Assignee:
RIKEN (JP)
AMBICION CO LTD (JP)
AMBICION CO LTD (JP)
International Classes:
C12N5/0786; A61K35/17; A61P35/00; A61P43/00; C12N5/0783
Domestic Patent References:
| WO2013162016A1 | 2013-10-31 | |||
| WO2006135032A1 | 2006-12-21 | |||
| WO2015035337A1 | 2015-03-12 |
Foreign References:
| JP2011503174A | 2011-01-27 |
Other References:
SPADA F.M. ET AL.: "Low expression level but potent antigen presenting function of CDld on monocyte lineage cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 30, 2000, pages 3468 - 3477, XP003026817
ASADA-MIKAMI R. ET AL.: "Increased expression of Va24+ T cells derived from G-CSF-mobilized peripheral blood stem cells as compared to peripheral blood mononuclear cells following alpha- galactosylceramide stimulation", CANCER SCIENCE, vol. 94, no. 4, 2003, pages 383 - 388, XP055434328
SPADA F.M. ET AL.: "CDld-restricted recognition of synthetic glycolipid antigens by human natural killer T cells", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 8, 1998, pages 1529 - 1534, XP055434329
See also references of EP 3453755A4
ASADA-MIKAMI R. ET AL.: "Increased expression of Va24+ T cells derived from G-CSF-mobilized peripheral blood stem cells as compared to peripheral blood mononuclear cells following alpha- galactosylceramide stimulation", CANCER SCIENCE, vol. 94, no. 4, 2003, pages 383 - 388, XP055434328
SPADA F.M. ET AL.: "CDld-restricted recognition of synthetic glycolipid antigens by human natural killer T cells", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 8, 1998, pages 1529 - 1534, XP055434329
See also references of EP 3453755A4
Attorney, Agent or Firm:
TAKASHIMA, Hajime (JP)
Download PDF: